Treatment of invasive streptococcal infection with a peptide derived from human high-molecular weight kininogen

Blood. 2009 Jul 9;114(2):444-51. doi: 10.1182/blood-2008-10-182527. Epub 2009 May 11.

Abstract

Sepsis and septic shock remain an important medical problem, emphasizing the need to identify novel therapeutic opportunities. Hypovolemic hypotension, coagulation dysfunction, disturbed microcirculation, and multiorgan failure resulting from vascular leakage are often observed in these severe conditions. In the present study, we find that HKH20, a peptide derived from human high molecular weight kininogen (HK), down-regulates inflammatory reactions caused by Streptococcus pyogenes in a mouse model of sepsis. HK is a component of the pro-inflammatory and pro-coagulant contact system. Activation of the contact system in the bloodstream by S pyogenes leads to massive tissue damage in the lungs of the infected mice, which eventually results in the death of the animals. HKH20 inhibits activation of the contact system and protects mice with invasive S pyogenes infection from lung damage. In combination with clindamycin treatment, the peptide also significantly prolongs the survival of infected mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Adhesion / drug effects
  • Female
  • Humans
  • Kininogen, High-Molecular-Weight / therapeutic use*
  • Lung Diseases / drug therapy
  • Lung Diseases / pathology
  • Mice
  • Mice, Inbred BALB C
  • Microscopy, Electron, Scanning
  • Peptide Fragments / therapeutic use*
  • Streptococcal Infections / drug therapy*
  • Streptococcal Infections / pathology*
  • Streptococcus pyogenes / drug effects
  • Survival Rate

Substances

  • Kininogen, High-Molecular-Weight
  • Peptide Fragments